Article (Scientific journals)
White Blood Cells in Patients Treated with Programmed Cell Death-1 Inhibitors for Non-small Cell Lung Cancer.
Sibille, Anne; Henket, Monique; Corhay, Jean-Louis et al.
2021In Lung, 199 (5), p. 549-557
Peer Reviewed verified by ORBi
 

Files


Full Text
SIBILLE 2021_White Blood Cells_Lung_ppediteur.pdf
Publisher postprint (947.38 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Apoptosis; Carcinoma, Non-Small-Cell Lung/drug therapy; Humans; Lung Neoplasms/drug therapy; Lymphocytes; Retrospective Studies; Checkpoint inhibitors; Non-small cell lung cancer; PD-1 inhibitors; Predictive marker; Prognostic marker; White blood cells
Abstract :
[en] PURPOSE: To investigate whether eosinophils and other white blood cell subtypes could be used as response and prognostic markers to anti-Programmed cell Death-1 or anti-PD-Ligand-1 treatments in non-small cell lung cancer patients. METHODS: We retrospectively analyzed data from the NSCLC patients consecutively treated at our hospital with a PD-1/PD-L1 inhibitor in monotherapy for advanced disease. A total of 191 patients were evaluated at three time-points to investigate any relation between tumor response and WBC counts. RESULTS: Baseline WBC and subtypes did not differ according to the type of response seen under treatment. A higher relative eosinophil count (REC) correlated with more objective responses (p = 0.019 at t1 and p = 0.014 at t2; OR for progression = 0.54 and 0.53, respectively) independently of the smoking status, PD-L1 status, and immune-related toxicity (IRT). Higher REC was also associated with a longer duration of treatment (p = 0.0096). Baseline absolute neutrophil count was prognostic (p = 0.049). At t1 relative lymphocytes, absolute and relative neutrophils, and neutrophil-to-lymphocyte ratio were prognostic (p = 0.044, p = 0.014, p = 0.0033, and p = 0.029, respectively). CONCLUSION: Our results show that in NSCLC patients anti-PD-1/PD-L1 therapy induces an early increase only in blood eosinophils, more prominent in responding patients and independent of the smoking status, PD-L1 status, and IRT. Eosinophils are also associated with a longer duration of treatment. Furthermore, our data support a prognostic role of neutrophils, lymphocytes, and their ratio for NSCLC patients with advanced disease treated with PD(L)-1 blockade.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Sibille, Anne  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
Henket, Monique ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie ; Department of Pulmonology, Laboratory Unit of Pulmonology, University Hospital of
Corhay, Jean-Louis ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
ALFIERI, Romain ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
Louis, Renaud ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
Duysinx, Bernard ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
Language :
English
Title :
White Blood Cells in Patients Treated with Programmed Cell Death-1 Inhibitors for Non-small Cell Lung Cancer.
Publication date :
October 2021
Journal title :
Lung
ISSN :
0341-2040
eISSN :
1432-1750
Publisher :
Springer, United States - Delaware
Volume :
199
Issue :
5
Pages :
549-557
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
© 2021. The Author(s).
Available on ORBi :
since 13 February 2023

Statistics


Number of views
132 (2 by ULiège)
Number of downloads
90 (1 by ULiège)

Scopus citations®
 
7
Scopus citations®
without self-citations
6
OpenCitations
 
3

Bibliography


Similar publications



Contact ORBi